Skip to content
Surviving the digital therapeutics graveyard—and thriving | David Benshoof Klein, Click Therapeutics

Surviving the digital therapeutics graveyard—and thriving | David Benshoof Klein, Click Therapeutics

Christina Farr talks with David Benshoof Klein, Founder and CEO of Click Therapeutics, days after the FDA cleared Motivista, the first authorized treatment for the negative symptoms of schizophrenia.
• 2 min read •
`

Upcoming Sessions

Live conversations with the people shaping healthcare.

View all →

Share this article

Spread the word